Antzelevitch Charles
Masonic Medical Research Laboratory, Utica, New York 13501, USA.
Expert Rev Cardiovasc Ther. 2003 Jul;1(2):177-85. doi: 10.1586/14779072.1.2.177.
Brugada syndrome, first described as a new clinical entity by Pedro and Josep Brugada in 1992, has attracted great interest because of its high prevalence in many regions of the world and its association with high risk for sudden death. The syndrome has captured the attention of the cardiac electrophysiology community because it serves as a paradigm for our understanding of the role of spatial dispersion of repolarization in the development of cardiac arrhythmias. The past decade has witnessed an exponential rise in the number of reported cases and a striking proliferation of papers serving to define the clinical, genetic, cellular, ionic and molecular aspects of this disease. This brief review summarizes the key clinical and experimental milestones that have brought us to our current understanding and approach to therapy of the Brugada syndrome.
1992年，佩德罗（Pedro）和何塞普·布鲁加达（Josep Brugada）首次将布鲁加达综合征描述为一种新的临床实体。由于其在世界许多地区的高患病率以及与猝死高风险的关联，该综合征引起了极大关注。该综合征引起了心脏电生理学界的关注，因为它是我们理解复极空间离散在心律失常发生中作用的范例。在过去十年中，报告病例数呈指数级增长，用于定义该疾病临床、遗传、细胞、离子和分子方面的论文也大量涌现。这篇简短综述总结了一些关键的临床和实验里程碑，这些里程碑使我们对布鲁加达综合征有了目前的认识和治疗方法。
